WallStSmart
IKT

Inhibikase Therapeutics Inc

NASDAQ: IKT · HEALTHCARE · BIOTECHNOLOGY

$1.93
-0.52% today

Updated 2026-05-05

Market cap
$254.82M
P/E ratio
P/S ratio
10.39x
EPS (TTM)
$-0.49
Dividend yield
52W range
$1 – $2
Volume
1.4M

Inhibikase Therapeutics Inc (IKT) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
3 of 8
Last 8 quarters
Avg EPS surprise
-20.5%
Last 4 quarters
Revenue YoY growth
Most recent quarter
EPS YoY growth
+48.5%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
-4.3%
Last 2 reports
Positive reaction rate
0%
0 of 2 quarters
Largest single-day move
-5.6%
2025-11-13
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-27$-0.09+23.9%$1.63$1.58-3.1%
2025-11-13$-0.13-1.9%$1.62$1.53-5.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.12$-0.09+23.9%
2025-09-30$-0.13$-0.13-1.9%
2025-06-30$-0.08$-0.11-37.5%
2025-03-31$-0.09$-0.15-66.7%
2024-12-31$-0.09$-0.17-101.7%$26274.00+2627300.0%
2024-09-30$-0.48$-0.65-35.4%
2024-06-30$-0.67$-0.66+1.5%
2024-03-31$-0.79$-0.73+7.6%
2023-12-31$-0.85$-0.64+24.7%$1.00
2023-09-30$-1.12$-0.86+23.2%$79569.00
2023-06-30$-0.92$-1.11-20.7%$116410.00
2023-03-31$-0.14$-0.16-14.3%$64520.00

Frequently asked questions

Has Inhibikase Therapeutics Inc beaten earnings estimates?
Inhibikase Therapeutics Inc has beaten Wall Street EPS estimates in 3 of its last 8 quarterly reports, with an average EPS surprise of -20.5% over the last 4 quarters.
How does IKT stock react to earnings?
IKT stock has moved an average of -4.3% in the trading day following earnings over its last 2 reports, with positive reactions in 0% of those quarters.